CYD Dengue Vaccine (5-dose formulation) + Placebo, NaCl 0.9%
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dengue Fever
Conditions
Dengue Fever, Dengue Hemorrhagic Fever
Trial Timeline
Apr 14, 2016 → Oct 28, 2018
NCT ID
NCT02623725About CYD Dengue Vaccine (5-dose formulation) + Placebo, NaCl 0.9%
CYD Dengue Vaccine (5-dose formulation) + Placebo, NaCl 0.9% is a phase 2 stage product being developed by Sanofi for Dengue Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT02623725. Target conditions include Dengue Fever, Dengue Hemorrhagic Fever.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02623725 | Phase 2 | Completed |
Competing Products
20 competing products in Dengue Fever